

print. I've tried to corroborate his figures but can't. Not because no one will give me the data, but because no one appears to have them. Yet they are, thanks to Jacobson, now part of the public record—to be quoted and requoted.

I suspect it will take more than one or even a series of editorials in *Science* to change the public image of our food supply—a potpourri of carcinogens.

MELVIN A. BENARDE

Department of Community Medicine and Environmental Health, Hahnemann Medical College & Hospital of Philadelphia, Philadelphia, Pennsylvania 19102

References

1. *Philadelphia Bulletin*, 21 October 1979, p. 10.

Biotechnology and Profit

There is one aspect which I thought was omitted from the otherwise complete factual account by Nicholas Wade (*News and Comment*, 9 Nov., p. 663) of the founding, funding, and management of research of the smaller new biotechnological companies. Much of what these companies are doing is based on fundamental research, mostly the use of restriction enzymes in recombinant DNA work, research funded by public moneys, some of it I am sure in direct grants to some of the biologists who are now so involved with these companies. This is how it has been with pharmaceutical companies; there is no bar against this, but it seems to me that there is an ethical principle being violated. That principle has to do with the reason why public money is being spent on biological research; namely, that the fruits of this research will be available to the public who has supported it. Of course it will be available, but in the process, there will be profits, great and small, for the companies involved and, I gather, for some of the individual scientists involved. Of course the public will eventually benefit if, for example, a large supply of insulin is available; but at what price?

Now that these companies are set up and are going concerns, may I suggest to those scientists who either manage the companies, sit on their boards, or advise them, that they see to it that the profit margins to the investors are small; and that if large profits accrue, that these be placed in research funds to be plowed back into basic research, preferably to support young scientists who have not had the opportunity to dip into the public trough for private gain.

WORKSHOP ON GENETIC AND CYTOGENETIC TOXICOLOGY

BROOKHAVEN NATIONAL LABORATORY

Upton, Long Island, New York

February 25–29, 1980

A one-week lecture program will be presented covering the principal methods in current use in genetic toxicology testing with special emphasis on in vivo and in vitro cytogenetic methods.

A second week (March 3–7) of intensive laboratory work will be available to a small number of applicants who attend the lecture series.

The Workshop staff will include both Brookhaven National Laboratory personnel and distinguished lecturers from other institutions. A fee of \$350 will be charged for the lecture program, and will include housing. There will be an additional fee for those accepted for the second week's laboratory training.

For applications and further information, write to:

Dr. M. A. Bender, Medical Department
Brookhaven National Laboratory
Associated Universities, Inc., Upton, L.I., NY 11973



Circle No. 363 on Readers' Service Card

COMBATING THE #1 KILLER

The SCIENCE
Report on
Heart
Research

JEAN L. MARX and
GINA BARI KOLATA

— a direct, unbiased report with information for all
investigators in the field, makers of public policy, scientists
and the general public.

\$17.00 casebound \$7.50 paperbound
10% discount to AAAS members


Send name, address and remittance to

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE



Department B-3
1515 Massachusetts Avenue, NW
Washington, D.C. 20005

In the time it takes you to read this ad you could have loaded 20 samples onto your electrofocusing gel



That's how easy it is with LKB's Multiphor® unit. And duration of the runs is also short: the precisely engineered all-glass cooling stage means that you can apply higher power for faster runs—higher field strengths for sharper resolution. With the Multiphor unit and LKB's power supply you can do up to 48 samples in less than two hours!

Besides being the system of choice for analytical and preparative electrofocusing, the Multiphor unit is excellent for electrophoresis as well. Simply add the required kit and you're ready to work with SDS-polyacrylamide gels, agarose gels — even immunoelectrophoretic methods.

For safety the Multiphor unit is also unique. There is no metal in the cooling stage to invite short circuits, the electrode design makes it almost impossible to come into contact with high voltage, and the power supply has a safety interlock so you can connect it to your own equipment without additional risk.

If you think that a system which offers so much in speed, reproducibility, versatility and safety has to be costly, think again. The Multiphor system is one of the least expensive flat bed instruments available. Send for details today. (And be sure to ask for pertinent LKB Application Notes, a free subscription to *Acta Ampholinæ* and information about forthcoming electrofocusing seminars and workshops.)



LKB Instruments Inc.
12221 Parklawn Drive Rockville, MD 20852
301: 881-2510

Circle No. 293 on Readers' Service Card

Finally, a debatable question must be raised based on the premise that there must be some avocations in a capitalistic society that are not tied in to the profit motive, and that scientific research, based on the socialistic principle of funding for the public good, must be one of them.

PHILIP SIEKEVITZ

Rockefeller University,
New York 10021

Cancer Risk Assessment

The controversy over the appropriate method for assessing cancer risks, as described in *Science* (News and Comment, 25 May, p. 811), cannot be resolved satisfactorily without considering the diverse causes that can lead to an apparent positive result in a bioassay for carcinogenicity. Indeed, the very term "bioassay" is unfortunate, in that it implies that chemicals which are "active" share one particular characteristic that can be quantified and mechanically extrapolated to yield an estimate of risk. Such interpretations, though possibly appealing to the decision-maker, lack credibility. If experiments were perceived as "investigations" of biological activities, rather than as "bioassays," studies would be designed differently and would yield information more meaningful to risk assessment. The resulting estimates, based on recognition of the differing kinds of effects chemicals can exert on the whole animal, would appear more believable than the rigid mathematical interpretations currently proposed.

A helpful perspective on the issue is afforded by considering certain analogies to infectious disease. Bacteriologists distinguish between pathogenic organisms and those incapable of causing illness. They also recognize "opportunistic" pathogens, those capable of infecting a host only if the defense of the host has been weakened. Virulence depends upon several factors, including the host species, and bacteriologists will pause before concluding that the risk to humans is the same as that observed for another mammal. They certainly do not view all pathogens as representing an equal health hazard and know that the progression of an infection depends upon more factors than just the size of the inoculum (exposure). Death associated with infectious disease, just as death from cancer, frequently occurs under conditions (impaired defenses) which indicate that such infection should be viewed as a symptom rather than the cause of an organism's failing. Nobody